Welcome to BeiMedPlus

Poster from ESMO Immuno-oncology 2021 investigating the effects of inhibiting PD-1 and TIGIT in combination with chemotherapy for unresectable non-small cell lung cancer (NSCLC).

Poster presented at ESMO 2021 investigating the potential for dual targeting of metastatic non-small cell lung cancer (NSCLC) with receptor tyrosine kinase inhibitors (RTKis) and PD-1 inhibitors.

Poster presented at ESMO 2021 describing the potential for the dual targeting of refractory/resistant (R/R) metastatic non-small cell lung cancer (NSCLC) with receptor tyrosine kinase inhibitors (RTKis) and PD-1 inhibitors.

The Satellite Symposium at BSH 2022 provided expert insights into treatment options in Waldenström's macroglobulinemia (WM), the emerging role of BTKis in WM, and BTKi-associated adverse events and their management.